Azacitidine with or without lenalidomide in higher risk myelodysplastic syndrome & low blast acute myeloid leukemia

Standard treatment for higher risk myelodysplastic syndromes, chronic myelomonocytic leukemia and low blast acute myeloid leukemia is azacitidine. In single arm studies, adding lenalidomide had been suggested to improve outcomes. The ALLG MDS4 phase II trial randomized such patients to standard azac...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Haematologica
Главные авторы: Kenealy, Melita, Hertzberg, Mark, Benson, Warwick, Taylor, Kerry, Cunningham, Ilona, Stevenson, Will, Hiwase, Devendra, Eek, Richard, Zantomio, Daniela, Jong, Steve, Wall, Meaghan, Blombery, Piers, Gerber, Tracey, Debrincat, Marlyse, Zannino, Diana, Seymour, John F.
Формат: Artigo
Язык:Inglês
Опубликовано: Ferrata Storti Foundation 2019
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442982/
https://ncbi.nlm.nih.gov/pubmed/30545923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.201152
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы